The HAP1 Knockout HEK293T Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population in which the HAP1 (huntingtin-associated protein 1) gene has been disrupted. This polyclonal knockout pool contains a heterogeneous mixture of HEK293T cells harboring diverse loss-of-function editing events at the HAP1 locus, generated using CRISPR/Cas9-mediated gene disruption. Unlike monoclonal knockout cell lines, the polyclonal format enables researchers to study bulk population-level effects of HAP1 ablation while mitigating clonal variation. The cells are supplied as a ready-to-use pooled knockout population suitable for immediate expansion and downstream functional assays.
The host cell line employed for this knockout product is HEK293T, a widely utilized human embryonic kidney cell line transformed with adenovirus 5 and SV40 large T antigen. HEK293T cells are renowned for their high transfection efficiency, robust protein expression capacity, and proficiency in retroviral and lentiviral packaging. These characteristics make HEK293T a versatile mammalian cell model for studying intracellular processes, including signal transduction, protein?Cprotein interactions, and vesicle transport. The stable, rapid growth and easy maintenance of HEK293T cells further enhance their utility in routine cell-based assays and high-throughput screening formats.
HAP1 functions as a critical adaptor protein that links huntingtin (HTT) to the dynein/dynactin and kinesin motor complexes, thereby orchestrating the bidirectional microtubule-dependent transport of signaling endosomes. In particular, HAP1 mediates the intracellular trafficking of BDNF/TrkB endosomes, a process essential for neurotrophic signal propagation. HAP1 directly interacts with huntingtin, dynactin, kinesin, dynein, clathrin, and TrkB, and it regulates TrkB internalization and retrograde transport. Upstream activation by BDNF triggers this machinery, while downstream consequences include modulation of PI3K/Akt signaling and regulation of synaptic protein localization. In Huntington??s disease, mutant huntingtin disrupts HAP1 function, compromising neurotrophic signaling and exacerbating neurodegeneration.
In the HEK293T background, CRISPR/Cas9-mediated disruption of HAP1 impairs the microtubule-dependent trafficking of associated cargoes, including BDNF/TrkB endosomes. Although HEK293T cells are of non-neuronal origin, they express core components of the trafficking machinery and are amenable to detailed mechanistic dissection. Loss of HAP1 in this model is expected to attenuate retrograde and anterograde vesicle movement, potentially altering the subcellular distribution of TrkB and dampening downstream Akt phosphorylation. Consequently, this knockout pool serves as a tractable system for investigating huntingtin?CHAP1 interactions and for screening small-molecule modulators that might restore proper trafficking in neurodegeneration-relevant contexts.
The HAP1 Knockout HEK293T Polyclonal Cells are ideally suited for a range of advanced research applications, including Huntington??s disease studies, mechanistic investigations of neuronal trafficking, and drug screening. Key assay formats include western blotting to assess HAP1 and phospho-Akt levels, immunofluorescence to visualize TrkB mislocalization, co-immunoprecipitation to confirm disrupted HAP1?Chuntingtin binding, live-cell imaging to track vesicle movement, and flow cytometry to measure surface receptor changes. This polyclonal knockout population is also amenable to high-throughput screening of small molecules that restore proper trafficking or neurotrophic signaling. For additional details or custom inquiries, please contact Ascent Research.
